Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 22 | 13 | +0,17 % | ||
| UNIQURE | 11 | - | -8,81 % | ||
| SAREPTA THERAPEUTICS | 10 | 1 | -36,93 % | ||
| SYNDAX PHARMACEUTICALS | 10 | 1 | -4,17 % | ||
| CASTLE BIOSCIENCES | 9 | 2 | +1,83 % | ||
| TERNS PHARMACEUTICALS | 9 | 2 | +9,02 % | ||
| AVADEL PHARMACEUTICALS | 8 | 6 | -0,61 % | ||
| KURA ONCOLOGY | 8 | 2 | +0,24 % | ||
| HALOZYME THERAPEUTICS | 7 | 6 | +0,28 % | ||
| INCYTE | 6 | 25 | +1,70 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:12 | Royalty Pharma Acquires 1% Royalty Interest In Alnylam's Amvuttra For $310 Mln | 13 | AFX News | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX), on Tuesday, announced the acquisition of a 1% royalty interest in Alnylam Pharmaceuticals Inc.'s (ALNY) Amvuttra from funds managed by Blackstone... ► Artikel lesen | |
| 14:06 | Esperion Therapeutics, Inc.: Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer | - | GlobeNewswire (Europe) | - Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance - ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today... ► Artikel lesen | |
| 14:06 | AC Immune GAAP EPS of -$0.16 beats by $0.07, revenue of $0.94M misses by $0.07M | 1 | Seeking Alpha | ||
| 14:06 | Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference | 64 | Business Wire | Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe... ► Artikel lesen | |
| 14:06 | Arcutis Biotherapeutics, Inc.: Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology | - | GlobeNewswire (Europe) | ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved... ► Artikel lesen | |
| 14:00 | Morning Market Movers: DENN, SRPT, JELD, ICHR See Big Swings | 56 | AFX News | CANBERA (dpa-AFX) - At 7:30 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 13:59 | Royalty Pharma Acquires 1% Royalty Interest In Alnylam's Amvuttra For $310 Mln | - | RTTNews | ||
| 13:59 | Harmony Biosciences Holdings, Inc Bottom Line Advances In Q3 | - | RTTNews | ||
| 13:58 | Harmony Biosciences übertrifft Erwartungen deutlich - Aktie legt nach starken Q3-Zahlen zu | - | Investing.com Deutsch | ||
| 13:54 | Alnylam stock maintains Buy rating at H.C. Wainwright after strong Q3 results | 1 | Investing.com | ||
| 13:48 | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M | 2 | Seeking Alpha | ||
| 13:46 | Prelude-Aktie steigt nach exklusivem Optionsvertrag mit Incyte für JAK2-Programm | 2 | Investing.com Deutsch | ||
| 13:46 | H.C. Wainwright senkt Kursziel für uniQure nach FDA-Rückschlag auf 70 $ | 1 | Investing.com Deutsch | ||
| 13:42 | uniQure stock price target lowered to $70 at H.C. Wainwright on FDA setback | 1 | Investing.com | ||
| 13:42 | Royalty Pharma acquires AMVUTTRA royalty interest for $310 million | 1 | Investing.com | ||
| 13:42 | Guggenheim raises Pyxis Oncology stock price target to $7 on expanded trial data | 1 | Investing.com | ||
| 13:36 | Amicus Therapeutics Non-GAAP EPS of $0.18 beats by $0.06, revenue of $169.06M beats by $3.35M | 1 | Seeking Alpha | ||
| 13:36 | Taysha Gene Therapies GAAP EPS of -$0.09 in-line | 1 | Seeking Alpha | ||
| 13:22 | Novavax schließt Transfer der US-Zulassung für COVID-Impfstoff an Sanofi ab | 10 | Investing.com Deutsch | ||
| 13:22 | Pacira BioSciences sichert sich Lizenz für neuartige Formulierung zur Langzeit-Schmerzkontrolle | 4 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .